HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

montelukast (Singulair)

Subscribe to New Research on montelukast

a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source

Also Known As:

Singulair; Cahill May Roberts brand of montelukast sodium; MK 0476; MK-0476; Merck Frosst brand of montelukast sodium; Merck Sharp & Dohme brand of montelukast sodium; Merck brand of montelukast sodium; montelukast sodium; sodium 1-(((1-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)-3-(2-(1-hydroxy-1-methylethyl)phenyl)propyl)thio)methyl)cyclopropylacetate

Networked: 1091 relevant articles (269 outcomes, 362 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Reiss, Theodore F: 26 articles (04/2012 - 01/2002)
2.	Philip, George: 17 articles (03/2013 - 06/2002)
3.	Szefler, Stanley J: 15 articles (01/2013 - 02/2003)
4.	Dass, S Balachandra: 15 articles (02/2010 - 10/2003)
5.	Reiss, T F: 14 articles (07/2009 - 04/2000)
6.	Lipworth, B J: 13 articles (06/2007 - 09/2000)
7.	Zeiger, Robert S: 12 articles (01/2011 - 09/2004)
8.	Sorkness, Christine A: 11 articles (01/2011 - 02/2005)
9.	Stelmach, Iwona: 10 articles (04/2015 - 02/2002)
10.	Smugar, Steven S: 10 articles (08/2012 - 05/2009)

Related Diseases

1.	Asthma (Bronchial Asthma) 11/01/2006 - "Following treatment with 10mg montelukast 86.5% (n=4547) of patients reported a strong or marked improvement in day-time asthma symptoms and 88.5% (n=4367) reported improvement in night-time symptoms. " 01/01/2001 - "Montelukast, a new leukotriene modifier, has several benefits in the treatment of asthma in adults and children including improved relief of asthma symptoms, rapid onset, a safety profile comparable with placebo, and oral, once-daily dosing means excellent adherence." 11/01/2010 - "Add-on montelukast demonstrated significant improvement in asthma symptoms over 12 months in all patients in the study. " 03/01/2010 - "This open-label, multicenter observational study shows significant improvement in six QoL parameters evaluated by the physicians and in 13 out of 15 QoL categories judged by the patients 3-5 months after adding montelukast to the ongoing asthma treatment in patients with mild or moderate persistent asthma. " 04/01/2008 - "By the end of the study, which consisted of montelukast treatment, a significant improvement over baseline was noted in asthma symptoms and severity, as well as in treatment compliance. "
2.	Rhinitis 02/01/2003 - "The treatment effect of montelukast was significantly greater (P < 0.05), relative to placebo, for all secondary endpoints, including nighttime symptoms and daytime eye symptoms, patient and physician global evaluations of allergic rhinitis, and rhinoconjunctivitis quality of life. " 12/01/2005 - "Montelukast treatment also improved global evaluations of allergic rhinitis by patients and Rhinoconjunctivitis Quality of Life Questionnaire scores: differences vs the placebo group were -0.15 (95% CI, -0.27 to -0.04; P < .01) and -0.15 (95% CI, -0.24 to -0.06; P < .001), respectively. " 06/01/2006 - "Recent studies have demonstrated that montelukast is also effective in treating daytime and nighttime allergic rhinitis (AR) symptoms in asthmatic patients. " 03/01/2014 - "This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis. " 12/01/2013 - "This study tested inhibitory effects of in vitro Montelukast treatment on nasal airway epithelial cells (AEC) cultured from asthmatic patients treated with Montelukast with and without concomitant allergic rhinitis. "
3.	Inflammation 01/01/2010 - "While fish oil and montelukast are both effective in attenuating airway inflammation and HIB, combining fish oil with montelukast did not confer a greater protective effect than either intervention alone. " 07/01/2006 - "Other therapies, including montelukast, partial dietary elimination, and bouginage have reduced symptoms without affecting mucosal inflammation. " 05/01/2006 - "Montelukast reduced the severity of airway inflammation and the number of eosinophils in asthmatic guinea pigs. " 11/01/2002 - "In a number of clinical experiments, montelukast not only improved asthmatic symptoms and respiratory indices, but also inhibited airway inflammation and exercise-induced bronchoconstriction. " 01/01/2013 - "Furthermore, considerable deviations were observed for the recuperation of TM and mucosal inflammation for groups in which subjects were injected with montelukast as compared to other groups of the study in the late phases. "
4.	Seasonal Allergic Rhinitis (Hay Fever) 12/01/2006 - "Montelukast treatment provided significant improvement in symptoms and peripheral eosinophil counts of school-age children with seasonal allergic rhinitis; however, it did not show a significant effect on eNO levels." 03/01/2004 - "Montelukast significantly improved daytime nasal symptoms score in patients with seasonal allergic rhinitis, and the effect was greater in patients exposed to higher pollen levels." 09/01/2008 - "Both montelukast 5 mg and 10 mg doses show clinically meaningful efficacy for the treatment of patients with seasonal allergic rhinitis and the safety profiles of those are comparable to that of the placebo." 11/01/2005 - "Montelukast effectively treats the nighttime impact of seasonal allergic rhinitis." 01/01/2005 - "Montelukast has shown efficacy for seasonal allergic rhinitis (SAR); however, onset of action for SAR has not been presented. "
5.	Urticaria (Hives) 06/01/2012 - "Efficacy of montelukast as added therapy in patients with chronic idiopathic urticaria." 10/01/2011 - "However in the subgroup of five patients with the most severe urticaria, defined as patients with symptom scores in the upper quartile at inclusion in the study, montelukast (41; 11 214) was superior to placebo (95.5; 48 230; p < 0.05), but only when using an in-house symptom score questionnaire and not when using a validated urticaria activity score questionnaire. " 07/01/2015 - "Montelukast: Chronic Urticaria." 06/01/2012 - "Almost half of our patients with chronic urticaria responded to montelukast and combined anti-H1 and anti-H2 therapy. " 06/01/2012 - "In 11 patients, montelukast had no effect and in 2 patients the urticaria worsened after montelukast was started. "

Related Drugs and Biologics

1.	fluticasone (Cutivate)
2.	Leukotriene Receptors (Leukotriene Receptor)
3.	salmeterol (Serevent)
4.	Adrenal Cortex Hormones (Corticosteroids)
5.	Budesonide (Pulmicort)
6.	Loratadine (Alavert)
7.	leukotriene D4 receptor (cysteinyl leukotriene receptor)
8.	Aspirin (Acetylsalicylic Acid)
9.	Leukotriene Antagonists (Leukotriene Receptor Antagonists)
10.	desloratadine (Aerius)

Related Therapies and Procedures

1.	Aftercare (After-Treatment)
2.	Nebulizers and Vaporizers (Inhaler)
3.	Immunotherapy
4.	Respiratory Therapy (Therapy, Respiratory)
5.	Prostheses and Implants (Prosthesis)